Wyeth Reduces Risk with Dyadem Software
TORONTO, Apr. 15 /PRNewswire-AsiaNet/ --
Dyadem, the market leader in Quality Lifecycle Management and Risk
Lifecycle Management solutions, has announced that Wyeth, a global leader in
prescription pharmaceuticals and non-prescription consumer health care
products, is using software from Dyadem to enhance and standardize its risk
assessments. Dyadem's PHA-Pro, a software solution that identifies, measures
and mitigates risk, enables Wyeth to set a new standard in safety for its
pharmaceutical products. Wyeth's industry-leading pharmaceutical and health
care products improve lives and deliver outstanding value to customers and
shareholders by leading the world in innovation through pharmaceutical,
biotech and vaccine technologies.
PHA-Pro is a software solution that delivers industry-standard Process
Hazard Analysis (PHA) capabilities for the process industries. The PHA
methodology is an integral part of a pharmaceutical manufacturer's Process
Safety Management program and results in safer and more predictable
production processes. Dyadem's PHA-Pro helps manage Risk Lifecycle Management
processes, and was built to reflect the risk mitigation initiatives and
operating environments of the various process industries. This is essential
to optimizing work time, minimizing work stoppages, and reducing the
potential for undesirable events, while improving the safety and quality of a
given product for consumers.
With PHA-Pro being used across their global organization, Wyeth has
integrated the knowledge and expertise of all departments into their PHA
studies and provided the Environmental Health and Safety department
visibility into the overall business process, making everyone at the company
more aware of their global business and safety strategy. "We needed a
systematic, methodical way to document our PHA studies," said Steven
Meszaros, Corporate Director, EHS (Environmental Health and Safety), Wyeth.
"With Dyadem's PHA-Pro, Wyeth has been able to establish a community of users
and a standardized approach to our PHA studies. It has allowed us to create a
benchmark for safety and quality for our company, which will ultimately
benefit our customers."
Having used PHA-Pro for many years, Wyeth has been able to continuously
improve their risk management program. The easy configuration of templates,
along with the application's industry-specific libraries and
report-generating features have allowed Wyeth to focus on their business
process and overall business strategy, instead of worrying about the
consistency of their PHA studies. Since implementing PHA-Pro, Wyeth has been
able to establish a best-practice platform which has proven to management the
value of a consistent hazard review process across the network.
"Wyeth's commitment to safety and visibility for all departments are some
of the reasons it has remained a leader in the pharmaceutical industry," said
Kevin North, President and CEO of Dyadem. "Pharmaceutical companies have
traditionally had challenges ensuring consistency and accuracy in their risk
assessments, but with our Risk Lifecycle Management solutions, we have given
the industry a chance to address this. Wyeth shows how important it is to
standardize risk mitigation initiatives, and provide an avenue for input from
all areas of a business. Through their commitment to product safety, Wyeth
proves how easy it is to create safe, quality products and still be on the
leading edge of innovation."
About Dyadem
Dyadem is the market leader in Quality Lifecycle Management and Risk
Lifecycle Management solutions. Dyadem provides software and services that
empower companies to manage quality, mitigate risks, achieve regulatory
compliance, plan for business continuity and improve profitability. Dyadem
works with 85% of the Fortune 500 companies and serves the high tech &
electronics, medical devices, oil and gas, chemical, automotive,
pharmaceutical and aerospace and defense industries. For more information,
About Wyeth
Wyeth is a global leader in prescription pharmaceuticals,
non-prescription consumer health care products, and pharmaceuticals for
animal health. Wyeth's products are sold in more than 145 countries, and its
product portfolio includes innovative treatments across a wide range of
therapeutic areas. Wyeth's worldwide resources include 47,500 employees,
manufacturing facilities on four continents, and a unique research and
technology base encompassing small molecules, biopharmaceuticals, genetic
engineering that will give us the next wave of innovative therapies, and
vaccines. With this depth of resources, Wyeth will continue to lead the way
in the development of novel therapies that address critical global health
For further information, contact:
Text 100 Public Relations
Kevin Doak
617.399.4931
dyadem@text100.com
SOURCE: Dyadem
CONTACT: Kevin Doak of Text 100 Public Relations,
for Dyadem,
+1-617-399-4931,
dyadem@text100.com
Translations:
NEWS 
